Skip to main content

Advertisement

SpringerLink
Log in

Incidence of interstitial pneumonitis in breast cancer patients treated with pegylated liposomal doxorubicin

  • Review Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Background

In clinical practice, chemotherapy-induced interstitial pneumonitis (CIIP) is rare, but it has a high mortality. It has been reported that pegylated liposomal doxorubicin (PLD) may induce interstitial pneumonitis in some cases. However, the relationship between PLD and CIIP in breast cancer is still unknown. This study aims to investigate the incidence of PLD-induced interstitial pneumonitis in breast cancer patients.

Methods

All cases of breast cancer with chemotherapy are collected in our hospital from January 2016 to October 2018, and 354 eligible patients were included in analysis. Patients were divided into two groups according to different chemotherapy regimens received: epirubicin plus cyclophosphamide with or without docetaxel (EC/EC-T group) and PLD plus cyclophosphamide with or without docetaxel (DC/DC-T group). Patients’ general information and clinical characteristics, as well as the incidence of interstitial pneumonitis were compared between the two groups.

Results

The symptomatic interstitial pneumonitis occurred in 12 patients who received DC/DC-T treatment with an incidence of 12.25% (12/98), while no interstitial pneumonitis occurred in EC/EC-T group (p < 0.001). Of the 12 patients, 4 patients developed interstitial pneumonitis after 3 cycles of chemotherapy,7 patients after 4 cycles and 1 patient after 5 cycles. The mean interval between the beginning of chemotherapy and the onset of CIIP was 3.75 cycles.

Conclusion

Clinicians should pay attention to CIIP in breast cancer patients who receive more than three cycles of chemotherapy regimens containing pegylated liposomal doxorubicin plus cyclophosphamide with or without docetaxel.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Jasra S, Anampa J (2018) Anthracycline use for early stage breast cancer in the modern era: a review. Curr Treat Options Oncol 19(6):30

    Article  Google Scholar 

  2. Yang F, Teves SS, Kemp CJ, Henikoff S (2014) Doxorubicin, DNA torsion, and chromatin dynamics. Biochim Biophys Acta 1845(1):84–89

    CAS  PubMed  Google Scholar 

  3. Inaba K, Arimoto T, Hoya M, Kawana K, Nakagawa S, Kozuma S, Taketani Y (2012) Interstitial pneumonitis induced by pegylated liposomal doxorubicin in a patient with recurrent ovarian cancer. Med Oncol. 29(2):1255–1257

    Article  Google Scholar 

  4. Rom J, Bechstein S, Domschke C et al (2014) Efficacy and toxicity profile of pegylated liposomal doxorubicin (Caelyx) in patients with advanced breast cancer. Anticancer Drugs 25(2):219–224

    Article  CAS  Google Scholar 

  5. O’Brien MER, Wigler N, Inbar M et al (2004) Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 15(3):440–449

    Article  Google Scholar 

  6. Mark M, Thürlimann B (2012) Fatal pneumonitis after treatment with pegylated liposomal doxorubicin in a patient with metastatic breast cancer in complete remission. Med Oncol 29(3):1477–1478

    Article  Google Scholar 

  7. Huober J, Schoch O, Templeton A, Spirig C, Thürlimann B (2010) Interstitial pneumonitis after treatment with bevacizumab and pegylated liposomal doxorubicin in a patient with metastatic breast cancer. Chemotherapy 56(1):69–70

    Article  CAS  Google Scholar 

  8. Vourlekis JS, Brown KK, Cool CD, Young DA, Cherniack RM, King TE, Schwarz MI (2000) Acute interstitial pneumonitis. Case series and review of the literature. Medcine (Baltimore) 79(6):369–378

    Article  CAS  Google Scholar 

  9. Yonemori K, Hirakawa A, Kawachi A, Kinoshita F, Okuma H, Nishikawa T, Tamura K, Fujiwara Y, Takebe N (2016) Drug induced interstitial lung disease in oncology phase I trials. Cancer Sci 107(12):1830–1836

    Article  CAS  Google Scholar 

  10. Christensen S, Pedersen L, Grijota M, Kornum JB, Beiderbeck A, Sørensen HT (2008) Incidence of interstitial pneumonitis among breast cancer patients: a 10-year Danish population-based cohort study. Br J Cancer 98(11):1870–1875

    Article  CAS  Google Scholar 

  11. Toi M, Shao Z, Hurvitz S, Tseng LM, Zhang Q, Shen K, Liu D, Feng J, Xu B, Wang X, Lee KS, Ng TY, Ridolfi A, Noel-Baron F, Ringeisen F, Jiang Z (2017) Efficacy and safety of everolimus in combination with trastuzumab and paclitaxel in Asian patients with HER2+ advanced breast cancer in BOLERO-1. Breast Cancer Res 19(1):47

    Article  Google Scholar 

  12. Kim S, Tannock I, Sridhar S, Seki J, Bordeleau L (2012) Chemotherapy-induced infiltrative pneumonitis cases in breast cancer patients. J Oncol Pharm Pract 18(2):311–315

    Article  Google Scholar 

  13. Berenson JR, Yellin O, Kazamel T, Hilger JD, Chen CS, Cartmell A, Woliver T, Flam M, Bravin E, Nassir Y, Vescio R, Swift RA (2012) A phase 2 study of pegylated liposomal doxorubicin, bortezomib, dexamethasone and lenalidomide for patients with relapsed/refractory multiple myeloma. Leukemia 26(7):1675–1680

    Article  CAS  Google Scholar 

  14. Blum KA, Jung SH, Johnson JL, Lin TS, His ED, Lucas DM, Byrd JC, Cheson BD, Bartlett NL, Cancer and Leukemia Group B (2010) Serious pulmonary toxicity in patients with Hodgkin’s lymphoma with SGN-30, gemcitabine, vinorelbine, and pegylated liposomal doxorubicin is associated with an Fc gamma RIIIa-158 V/F polymorphism. Ann Oncol 21(11):2246–2254

    Article  CAS  Google Scholar 

  15. Mazzotta M, Giusti R, Iacono D, Lauro S, Marchetti P (2016) Pulmonary fibrosis after pegylated liposomal doxorubicin in elderly patient with cutaneous angiosarcoma. Case Rep Oncol Med 2016:8034832

    PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Breast and Thyroid Surgery, Shaoxing People’s Hospital (Shaoxing Hospital of Zhejiang University), Shaoxing, 312000, Zhejiang, People’s Republic of China

    Liwei Meng, Liming Huang, Yingchun Xu & Wei Zhang

Authors
  1. Liwei Meng
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Liming Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yingchun Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Wei Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Wei Zhang.

Ethics declarations

Conflict of interest

Author Liwei Meng declares that he has no conflict of interest. Author Liming Huang declares that he has no conflict of interest. Author Yingchun Xu declares that he has no conflict of interest. Author Wei Zhang declares that he has no conflict of interest.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Meng, L., Huang, L., Xu, Y. et al. Incidence of interstitial pneumonitis in breast cancer patients treated with pegylated liposomal doxorubicin. Cancer Chemother Pharmacol 85, 3–7 (2020). https://doi.org/10.1007/s00280-019-03909-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-019-03909-z

Keywords

Search

Navigation